While Daewoong Pharmaceutical and Seers Technology are making waves in Korea’s AI-powered hospital bed monitoring solution market, competitors Dong-A ST and MEZOO are drawing attention by rapidly expanding their market share in pursuit.

According to industry sources on the 20th, Dong-A ST has been rapidly increasing hospital deployments with “HiCardi,” an AI-based remote patient monitoring solution developed by Korean company MEZOO.

According to Dong-A ST, annual sales last year totaled 1,837 units, but the company sold 2,869 units in the first quarter of this year alone, surpassing last year’s total annual sales within a single quarter. This represents a 390.5% increase compared to the same period last year.

A Dong-A ST official stated, “We are accelerating our sales efforts with the goal of selling 10,000 units this year,” adding, “The solution has been receiving positive responses from both medical staff and patients.”

MEZOO provides a mobile remote patient monitoring solution capable of measuring and analyzing patients’ vital signs in real time. Since signing an exclusive distribution agreement with Dong-A ST, the company has rapidly expanded supply to domestic medical institutions. Its core products include the “HiCardi” series of patch-type patient monitoring devices and the “Live Studio” patient monitoring software platform. The company has adopted a subscription-based revenue model to reduce the initial implementation burden for healthcare institutions.

HiCardi is a patch-type wearable device attached to a patient’s body. It remotely monitors electrocardiogram (ECG), heart rate, arrhythmia, respiration, and fall detection in real time. Live Studio enables medical staff to simultaneously monitor patient conditions through dashboards and smartphones.